ALK- or ROS1-Positive Metastatic Non-Small Cell Lung Cancer: Crizotinib is indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education